Revlimid

MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed that the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%,

After discount row, NICE finally says yes to first line Revlimid

In a second piece of final draft guidance published today, NICE has also recommended Revlimid as a second line therapy with dexamethasone. ... However time is running out for Revlimid’s patent in Europe, which is due to expire in 2022, and could face

Orphan drugs market to soar to $224bn by 2024

The report also revealed other interesting developments, including Celgene toppling Novartis as the world’s biggest orphan drug developer as its multiple myeloma therapy Revlimid is predicted to be the leading ... Revlimid generated sales of $2.6bn in

Post-merger Celgene to lead pharma growth

Moody’s attributes Celgene's bright prospects to it strong late-stage pipeline, and continued growth from its blood cancer blockbuster Revlimid, despite fears of patent challenges to the drug, which ... The forecast has come ahead of Celgene’s Q1

BMS closes on Celgene merger after rebel investors bow out

News on Revlimid patent also positive. Bristol-Myers Squibb chalked up a morale-boosting victory in its bid to close its $74bn merger with Celgene, after a rebel investment group abandoned ... Both shareholders have said they are concerned about

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]